Last checked at 17 May 2016 07:00
PRESS RELEASE
17 May 2016
SYNAIRGEN PLC
("Synairgen" or "the Company")
Southampton, UK, 17 May 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 16 May 2016 it posted its full Audited Report and Accounts for the twelve months ended 31 December 2015 (the "Annual Report") to shareholders together with the Notice of Annual General Meeting ("AGM"). The Annual Report and Notice of AGM are also available on the Company's website www.synairgen.com.
The AGM will be held at the offices of Fladgate LLP, 16 Great Queen Street, London WC2B 5DG on 14 June 2016 at 11 am.
ENDS
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, James Thompson (Corporate Finance)
Stephen Norcross, Simon Johnson (Corporate Broking)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Jessica Hodgson / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology Biobank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The Biobank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com